All Clinical Trials:

A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Clinical Trial Protocol # ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

AALL1521, A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK PathwayMutant Acute Lymphoblastic Leukemia

Clinical Trial Protocol # AALL1521 | Adolescents and Young Adults, Leukemia | Contact (714) 509-8646

AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Clinical Trial Protocol # AALL1631 | Leukemia | Contact (714) 509-8646

ADVL1513, A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma

Clinical Trial Protocol # ADVL1513 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

ADVL1515 A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors

Clinical Trial Protocol # ADVL1515 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

ADVL1722/Eisai E7389G000223: A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) an

Clinical Trial Protocol # ADVL1722 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Clinical Trial Protocol # AGCT1531 | Solid Tumors | Contact (714) 509-8646

AHOD1721/BMS CA209744 – Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after

Clinical Trial Protocol # AHOD1721 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

ALTE1621, Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Clinical Trial Protocol # ALTE1621 | Late Effects | Contact (714) 509-8646

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects > 1 and < 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Clinical Trial Protocol # JNJ-54767414 | Adolescents and Young Adults, Leukemia/Lymphom, Recurrent/Refractory Cancer | Contact (714) 509-8646

ANBL1531, A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Clinical Trial Protocol # ANBL1531 | Solid Tumors | Contact (714) 509-8646

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

Clinical Trial Protocol # Head Start IV | Brain Tumor/Central Nervous System/Neuro-Oncology | Contact (714) 509-8646

Janssen LYM3003/Sparkle; A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma

Clinical Trial Protocol # LYM3003 | Lymphoma | Contact (714) 509-8646

Oncology Clinical Trial: A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Clinical Trial | Adolescents and Young Adults, Leukemia/Lymphoma, Recurrent/Refractory Cancer | Contact (714) 509-8646

Oncology Clinical Trial: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Clinical Trial Protocol # 10-CBA | Bone Marrow Transplant/Hematopoietic Stem Cell Transplant | Contact (714) 509-8646

Oncology Clinical Trial: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant or Intolerant to Imatinib

Clinical Trial Protocol # 90325 | Adolescents and Young Adults, Leukemia/Lymphoma, Recurrent/Refractory Cancer, oncology | Contact (714) 509-8646

Oncology Clinical Trial: A Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial | Bone Marrow Transplant/Hematopoietic Stem Cell Transplant | Contact (714) 509-8646

Oncology Clinical Trial: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)

Clinical Trial Protocol # MK3475-051/ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Oncology Clinical Trial: A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Clinical Trial Protocol # ADVL1416 | Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Oncology Clinical Trial: A Study on Drug Monitoring of Asparaginase Activity in Pediatric Patients with Acute Lymphoblastic Leukemia

Clinical Trial | Biology/Genomics, Leukemia/Lymphoma | Contact (714) 509-8646

Oncology Clinical Trial: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Clinical Trial | Solid Tumors | Contact (714) 509-8646

Oncology Clinical Trial: Approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer.

Clinical Trial | Survivorship | Contact (714) 509-8646

Oncology Clinical Trial: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Clinical Trial Protocol # ANBL00B1 | Biology/Genomics, Solid Tumors | Contact (714) 509-8646

Oncology Clinical Trial: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Clinical Trial Protocol # AALL1331 | Leukemia/Lymphoma, Recurrent/Refractory Cancer | Contact (714) 509-8646